Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Proxy Contest (June 2019)

8 slides from Progenics Pharmaceuticals's proxy contest presentation, Jun 24, 2019

  1. Slide 1: Velan's Lack of Experience in the Oncology Radiopharmaceutical Space Jeopardizes Progenics

    Progenics Velan’s Lack of Experience in the Oncology Radiopharmaceutical Space Jeopardizes the Long-Term Success of Progenics Progenics Find Fight and Follow"

  2. Slide 2: Disclosure notice

    Disclosure notice This presentation contains projections and other forward-looking statements” regarding future events. Statements containedin this communication thatreferto the estimated or anticipated future results or other non-historical facts of Progenics Pharmaceuticals, Inc. (‘Progenics’ or t

  3. Slide 3: Velan demonstrates a complete lack of understanding of the oncology & radiopharmaceutical space

    @ Velan demonstrates a complete lack of understanding « of the oncology & radiopharmaceutical space The development and commercialization of radiopharmaceuticals is not a cookie-cutter process, that can be generalized across unique and complex drugs Velan incorrectly draws comparisons to two drugs,

  4. Slide 4: Velan's comparison of AZEDRA to XOFIGO and LUTATHERA is deeply flawed

    Velan’s comparison of AZEDRA to XOFIGO and LUTATHERA is deeply flawed | Only compared drug that \ has Breakthrough Therapy | designation from the FDA ' Patient Location In-patient Radiation Dosage Large Ultra-orphan Neuroendocrine Tumors Indication Indicated Patient Size) | Narrow & Specific Out-pat

  5. Slide 5: Velan's criticisms of AZEDRA's commercialization process illustrate a poor understanding of the product

    Velan’s criticisms of AZEDRA’s commercialization process ilusteate a poor understanding of the product Acquires MIP Progenics’ Board and management saw value in MIP and eevee Assets ata acquired AZEDRA at a steep discount andmade Discount AZEDRA into the valuable asset it is today Receives FDA H———+

  6. Slide 6: Progenics has demonstrated a positive and financially sound rationale around the company's approach to 1095

    Progenics has demonstrated a positive and financially sound rationale around the company’s approach to 1095 Peter Mac Progenics aeeeee | Gea | peree | deeb Endooyte Progenics acquires MIP at ers: announces preweaty Goaurk® PSMAS17 enrolls st announces POR 2 ciscount comics nila or PRase2data acquire

  7. Slide 7: Velan has consistently prioritized control over improving the Board and creating value

    a ee ee Velan has consistently prioritized control over to improving the Board and creating value e While we disagree with Velan’s business points, we value their input into the composition of our board as a ~10% shareholder. This is why we made a generous offer to balance our valid ESG concerns aga

  8. Slide 8: Velan's shallow criticisms are illogical, contradictory or categorically untrue

    ee 7’ e Velan’s shallow criticisms are illogical, contradictory or — ye categorically untrue ¢ Velan fallaciously criticizes past sound decision-making that is driving real value creation today Pipeline * Velan argues the purchase of the Somerset facility should have been made prior to FDA approval,

Progenics Pharmaceuticals — Proxy Contest (June 2019) on 6ix